Commentary|Videos|November 20, 2026

Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer

Bridging the Gaps in Breast Cancer

Neil M. Iyengar, MD, discusses efficacy, sequencing, and tolerability questions for oral SERDs in early-stage breast cancer.

“Oral SERDs are really exciting because they’re better tolerated, and adherence might be better in the long run with those better-tolerated drugs.”

Neil M. Iyengar, MD, director of Survivorship Services at Winship Cancer Institute of Emory University and co-director of the Breast Medical Oncology Program at Emory University School of Medicine, discussed efficacy, sequencing, and tolerability questions surrounding oral selective estrogen receptor degraders (SERDs) in early-stage hormone receptor (HR)–positive breast cancer.

Iyengar first questioned whether oral SERDs could improve efficacy compared with standard endocrine therapies utilized in the early-stage setting. He cited the positive phase 3 lidERA Breast Cancer trial (NCT04961996), which investigated giredestrant (Wilserdly) as an up-front adjuvant approach. In June 2026, FDA granted priority review to a new drug application seeking the approval of giredestrant as adjuvant treatment for adult patients with estrogen receptor (ER)–positive, HER2-negative, stage I to III breast cancer, based on data from lidERA. A decision from the regulatory agency is anticipated by November 30, 2026.

The randomized, open-label trial enrolled 4170 patients with ER-positive, HER2-negative stage I to III breast cancer. Patients received giredestrant 30 mg daily or standard endocrine monotherapy, consisting of tamoxifen or an aromatase inhibitor, for 5 years. Premenopausal and perimenopausal women and men also received a luteinizing hormone–releasing hormone agonist. The primary end point was invasive disease-free survival (iDFS).

At a median follow-up of 32.3 months, giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard therapy (HR, 0.70; 95% CI, 0.57-0.87; P = .0014). The 3-year iDFS rates were 92.4% vs 89.6%, respectively. The distant recurrence-free interval also favored giredestrant (HR, 0.69; 95% CI, 0.54-0.89), while overall survival data were immature (HR, 0.79; 95% CI, 0.56-1.12). Treatment discontinuations due to adverse effects (AEs) occurred in 5.3% vs 8.2% of patients, respectively.

Beyond efficacy, Iyengar emphasized determining when to introduce an oral SERD. He contrasted upfront treatment, as evaluated in lidERA, with switch strategies in which patients began standard endocrine therapy before transitioning to an oral SERD. He noted that the relevance of switching could relate to the emergence of an ESR1 mutation, leaving the optimal timing and sequence as research questions.

Iyengar identified quality of life and tolerability as the third consideration, suggesting that these issues could be the most important for patients and clinical care. He explained that AEs associated with standard endocrine therapies contribute to treatment discontinuation and nonadherence.

He expressed enthusiasm for the potential tolerability improvement with oral SERDs, suggesting that better-tolerated drugs might improve adherence over the long term, linking their promise to patients’ ability to continue endocrine therapy.


Related to this article